Andreas Ejlegård: Rebalancing Thrombosis and Hemostasis Through Mechanistic Innovation
Andreas Ejlegård, Sales Development Manager at Rexel Sverige, shared a post on LinkedIn about recent articles by Michael Holinstat et al. , adding:
“Congratulations to Michael Holinstat on being named a 2026 Fellow of ACTS.
A well deserved recognition of his contributions to clinical and translational science.
His work with Cereno Scientific is particularly compelling across multiple programs.
With CS585, we are seeing a novel prostacyclin receptor approach that could prevent thrombosis without the traditional bleeding trade off.
Notably, the CS585 study was published in Blood, underscoring both the scientific quality and relevance of the findings.
At the same time, the recently published CS014 study in the Journal of Thrombosis and Haemostasis strengthens the broader thesis.
CS014, a next generation HDAC inhibitor, demonstrates potent antithrombotic effects while preserving normal haemostasis, effectively separating efficacy from bleeding risk.
Taken together, this is not incremental innovation.
It reflects a coordinated effort to target thrombosis, fibrosis, and vascular dysfunction at a mechanistic level.
These programs begin to approach something close to a ‘holy grail’ in cardiovascular medicine: effective thrombosis prevention without increased bleeding risk.”
1.Title: The oxylipin analog CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor
Authors: Livia Stanger, Adriana Yamaguchi, Pooja Yalavarthi, Sylviane Lambert, Devin Gilmore, Andrew Rickenberg, Catherine Luke, Kiran Kumar, Andrea T Obi, Andrew White, Niklas Bergh, Björn Dahlöf, Michael Holinstat
2.Title: Novel histone deacetylase inhibitor, CS014, attenuates in vivo thrombosis while maintaining hemostasis
Authors: Livia Stanger, Pooja Yalavarthi, Reheman Adili, Devin Gilmore, Timothy Hoang, Avery Campbell, Paul Krenik, David Gustafsson, Jan Fryklund, Tomas Fex, Nicholas Oakes, Jonas Faijerson Säljö, Björn Dahlöf, Joan Beckman, Michael Holinstat
Stay updated with all scientific advances Hemostasis Today.
-
Sep 8, 2026, 16:14Heghine Khachatryan: Colombo 2026 Insights on Point-of-Care Ultrasound in Hemophilia Joint Care
-
Sep 8, 2026, 15:57Flora Peyvandi: Efficiency Meets Innovation in Hemophilia B Gene Therapy
-
Sep 8, 2026, 15:48Maxime Dely: Guillain-Barré Syndrome – What if the Key Lies in the Plasma?
-
Sep 8, 2026, 15:34Ron DePinho: A Negative Trial Highlights the Need for Precision in Cardiovascular Inflammation
-
Sep 8, 2026, 15:31Adil Yousaf: Thrombolysis Speed Matters, but Eligibility Comes First
-
Sep 8, 2026, 15:28Dhargam Aljebouri: First Molecularly Characterized Para-Bombay Phenotype in the Arab World
-
Sep 8, 2026, 15:27Mohd Ashhad: How Much Does Hemoglobin Increase After 1 Unit of PRBC?
-
Sep 8, 2026, 15:27Sanish Babu: The Hematocrit–Platelet Signal in Severe Dengue
-
Sep 8, 2026, 15:26Mary Kama: Climate-Informed Early Warning Systems for Sickle Cell Anaemia